Unique pharmacokinetic profile

ZEGERID is the Only oral PPI that combines immediate release with the POWER of continued acid control - Night and Day

ZEGERID omeprazole capsules pharmacokinetics

Both capsules and powder for oral suspension are immediate-release formulations. Both facilitate immediate release of omeprazole for rapid absorption with peak plasma levels being reached in ~30 minutes
Built in buffer protects omeprazole from acid degradation by raising intragastric pH
No enteric coating on capsules or powder for oral suspension

Except for ZEGERID, all other PPIs are delayed release

Delayed-release proton pump inhibitors (PPIs) — including oral suspensions, disintegrating tablets, and capsules — require enteric coatings to protect against acid degradation
Enteric coatings delay absorption and initial acid suppression

Brand	Delayed-Release Formulations	Immediate-Release Formulations
ZEGERID® (omeprazole/sodium bicarbonate)	NA	Capsules, Powder for Oral Suspension
Nexium® (esomeprazole)	Capsules	NA
Prevacid® (lansoprazole)	Capsules, disintegrating tablets, oral suspension	NA
Protonix® (pantoprazole)	Tablets	NA
Aciphex® (rabeprazole)	Tablets	NA
Prilosec® (omeprazole)	Capsules	NA
*NA–Not available

Next page: Continued Acid Control

About ZEGERID | Is ZEGERID Right For Your Patients? | Patient Tools
| Important Safety Information

Please see full prescribing information.

You can obtain additional information about ZEGERID by writing Santarus directly. To speak to a representative by phone or to report an adverse event, call Santarus' Medical Information Department at 1.888.778.0887, option 2 (M-F, 9:00 am to 7:00 pm, EST).

Product Description
ZEGERID contains omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid, which raises the gastric pH and thus protects omeprazole from acid degradation.

Indications and Dosing for ZEGERID
ZEGERID is indicated for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
(20 mg); for the short-term treatment (4-8 weeks) of erosive esophagitis diagnosed by endoscopy
(20 mg); for maintenance of healing of erosive esophagitis (20 mg) (controlled studies do not extend beyond 12 months); for short-term treatment (4-8 weeks) of active duodenal ulcer (20 mg); for short-term treatment (4-8 weeks) of active benign gastric ulcer (40 mg); and for reduction of risk of upper gastrointestinal bleeding in critically ill patients (only powder for oral suspension 40 mg; use beyond 14 days has not been evaluated).

Important Safety Information about ZEGERID
The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal pain. In 178 critically ill patients treated with ZEGERID Powder for Oral Suspension, adverse events generally reflected the serious, underlying medical condition of the patients, and were similar for patients treated with ZEGERID Powder for Oral Suspension than in those treated with the comparator (acid-controlling) drug. For more information about these and other events, please see Table 13 of the Full Prescribing Information. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.

ZEGERID Capsules contain 304 mg of sodium per dose. ZEGERID Powder for Oral Suspension contains 460 mg of sodium per dose. This should be taken into consideration for patients on a sodium-restricted diet.

Sodium bicarbonate is contraindicated in patients with metabolic alkalosis and hypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation.

Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in capsules,
1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent to, and should not be substituted for, one 40 mg capsule, and two 20 mg packets are not equivalent to, and should not be substituted for, one 40 mg packet.